Can people with hypertrophic cardiomyopathy stop taking beta-blockers after mavacamten?
Part of Heart & circulation clinical trials.
This study looks at whether people with hypertrophic cardiomyopathy who are doing well on mavacamten can slowly reduce or stop their beta-blocker medication. The goal is to find out if it's safe and helps patients manage with fewer medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of heart disease called obstructive hypertrophic cardiomyopathy (a condition where the heart muscle is thickened and blocks blood flow).
- You've been on a medication called mavacamten for at least 12 weeks, with a stable dose for the past 8 weeks.
- You've been taking one beta-blocker (a heart medication) continuously for at least 4 weeks, with no changes.
- You are not taking a calcium channel blocker (another type of heart medication) at the same time.
- Your last heart ultrasound showed good heart function (ejection fraction of 55% or higher) and acceptable blood flow blockage levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at adults with a heart condition called obstructive hypertrophic cardiomyopathy. It tracks what happens after they start taking the medicine mavacamten, to learn more about its effects and how it works in real life.
This study looks at whether adjusting the dose of mavacamten based on heart function helps people with obstructive hypertrophic cardiomyopathy feel better and have fewer side effects. It is for people who are already on mavacamten and want to see if a personalized dose approach works.
This study collects blood samples and medical information from people with obstructive hypertrophic cardiomyopathy to learn why the medication mavacamten works differently in different people. The goal is to understand how genes and other factors influence treatment response, which may help personalize care.
This study looks at how mavacamten (a heart medication) works for people with obstructive hypertrophic cardiomyopathy (HCM)—a condition where heart muscle becomes too thick. Researchers will review medical records and ask patients about their experiences with the treatment.
This study tracks the safety of Mavacamten in people with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle thickens and blocks blood flow). It helps doctors understand how the drug works in everyday use in Japan.
This study tests whether mavacamten, a medication that may help the heart use energy better, can improve symptoms in people with obstructive hypertrophic cardiomyopathy. It aims to see if this drug helps with chest pain and shortness of breath, and improve overall heart function.
Hear when a new Obstructive Hypertrophic Cardiomyopathy (oHCM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.